cyclophosphamide + docetaxel + nab-paclitaxel + pegylated liposomal doxorubicin + pertuzumab + trastuzumab

This is a multi-agent combination chemotherapy and targeted therapy regimen used in the treatment of HER2-positive breast cancer, particularly in advanced or metastatic settings. The regimen includes: - Cyclophosphamide, an alkylating agent that crosslinks DNA to inhibit cell division. - Docetaxel and nab-paclitaxel, both taxane-class microtubule inhibitors that disrupt mitosis. - Pegylated liposomal doxorubicin, an anthracycline antibiotic encapsulated in pegylated liposomes for improved pharmacokinetics and reduced cardiotoxicity; it inhibits topoisomerase II and intercalates DNA[6][8]. - Pertuzumab and trastuzumab, monoclonal antibodies targeting the human epidermal growth factor receptor 2 (HER2), blocking its signaling to inhibit tumor cell proliferation[1][2][4]. This combination leverages cytotoxic chemotherapy with dual HER2 blockade for synergistic antitumor activity. It is primarily indicated for HER2-positive breast cancer but may be considered in other solid tumors expressing HER2.